Yep the results were very mediocre
Active vs Placebo
18.5% vs 8.2%
16.6% vs 3.6%
Bring on Brilacidin in larger studies and against placebo, as a foam/oral, and we possibly could triple their Remission scores based on interim results ...
Will dig a bit and see what criteria / how Pfizer defined Remission -- with or without Endoscopy
--
In OCTAVE Induction 1, a statistically significant and greater proportion of patients receiving tofacitinib 10 mg BID (18.5%) were in remission at Week 8, compared to 8.2% receiving placebo (p=0.007).1g Similar results were observed in OCTAVE Induction 2, with 16.6% of patients receiving tofacitinib 10 mg BID achieving remission at Week 8, compared to 3.6% receiving placebo (p<0.001).1h
Market Data 
Markets 
AI
